JPS517113A - - Google Patents
Info
- Publication number
- JPS517113A JPS517113A JP50067731A JP6773175A JPS517113A JP S517113 A JPS517113 A JP S517113A JP 50067731 A JP50067731 A JP 50067731A JP 6773175 A JP6773175 A JP 6773175A JP S517113 A JPS517113 A JP S517113A
- Authority
- JP
- Japan
- Prior art keywords
- june
- blood plasma
- water
- intravascularly
- subsequent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940039227 diagnostic agent Drugs 0.000 abstract 2
- 239000000032 diagnostic agent Substances 0.000 abstract 2
- 210000002381 plasma Anatomy 0.000 abstract 2
- 230000002285 radioactive effect Effects 0.000 abstract 2
- 239000004382 Amylase Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/003—Crosslinking of starch
- C08B31/006—Crosslinking of derivatives of starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Nanotechnology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7407461A SE420566B (sv) | 1974-06-06 | 1974-06-06 | Diagnostiseringsmedel for intravaskuler administrering |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS517113A true JPS517113A (enExample) | 1976-01-21 |
Family
ID=20321348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50067731A Pending JPS517113A (enExample) | 1974-06-06 | 1975-06-06 |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS517113A (enExample) |
| AU (1) | AU8164675A (enExample) |
| CA (1) | CA1039274A (enExample) |
| DE (1) | DE2524278A1 (enExample) |
| FR (1) | FR2273516A1 (enExample) |
| GB (1) | GB1518813A (enExample) |
| NL (1) | NL7506743A (enExample) |
| SE (1) | SE420566B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6075436A (ja) * | 1983-07-13 | 1985-04-27 | グルベ ソシエテ アノニム | 治療用塞栓化組成物 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0093757A1 (en) * | 1981-11-12 | 1983-11-16 | Ulf SCHRÖDER | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
| SE463651B (sv) * | 1983-12-21 | 1991-01-07 | Nycomed As | Diagnostikum och kontrastmedel |
-
1974
- 1974-06-06 SE SE7407461A patent/SE420566B/xx unknown
-
1975
- 1975-05-29 AU AU81646/75A patent/AU8164675A/en not_active Expired
- 1975-05-31 DE DE19752524278 patent/DE2524278A1/de not_active Withdrawn
- 1975-06-05 FR FR7517632A patent/FR2273516A1/fr active Granted
- 1975-06-05 GB GB24287/75A patent/GB1518813A/en not_active Expired
- 1975-06-05 CA CA228,779A patent/CA1039274A/en not_active Expired
- 1975-06-06 JP JP50067731A patent/JPS517113A/ja active Pending
- 1975-06-06 NL NL7506743A patent/NL7506743A/xx not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6075436A (ja) * | 1983-07-13 | 1985-04-27 | グルベ ソシエテ アノニム | 治療用塞栓化組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2273516B1 (enExample) | 1979-01-05 |
| NL7506743A (nl) | 1975-12-09 |
| SE420566B (sv) | 1981-10-19 |
| SE7407461L (sv) | 1975-12-08 |
| FR2273516A1 (fr) | 1976-01-02 |
| CA1039274A (en) | 1978-09-26 |
| GB1518813A (en) | 1978-07-26 |
| DE2524278A1 (de) | 1975-12-18 |
| AU8164675A (en) | 1976-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0787017B2 (en) | Diagnostic preparation for detection of helicobacter pylori | |
| DE69620467T2 (de) | Radionuklidmarkierung von vitamin b12 und deren coenzyme | |
| CA1165686A (en) | Radioactive diagnostic agent and non-radioactive carrier therefor | |
| JPS60155138A (ja) | 高められた腸内吸収性を有するヘパリン製剤の製造方法及び該ヘパリン製剤 | |
| US4071613A (en) | Stabilized alcohol solution of reducing salt formulations for use in preparing radioisotope labeled scanning agents: liver scanning technetium-99m colloid and method of preparation | |
| GB1518813A (en) | Diagnostic agent | |
| Ekenved | ABSORPTION FROM DIFFERENT TYPES OF IRON TABLETS‐CORRELATION BETWEEN SERUM IRON INCREASE AND TOTAL ABSORPTION OF IRON | |
| Rajewsky | Researches in the problem of radium poisoning and the tolerance dose of radium | |
| EP0063946A1 (en) | Diagnosis of kidney function | |
| DE69001000T2 (de) | Radioaktives diagnosemittel. | |
| Wingårdh et al. | Evaluation in vitro and in vivo of two labelling techniques of different 99mTc-dextrans for lymphoscintigraphy | |
| US4057618A (en) | Radioiodinated bleomycin | |
| JPS5842846B2 (ja) | 肝臓および骨髄走査用テクネチウム−99m標識放射線診断剤とその製造法 | |
| Balaban et al. | Effect of the radiolabel mediator tropolone on lymphocyte structure and function | |
| Caputo et al. | Letterer-Siwe disease in an octogenarian | |
| Hudson et al. | Tumour uptake of thallium-201 chloride | |
| GB2055044A (en) | Glucuronidase activity and/or phdependent pharmaceuticals and their methods of production and use for selective treatment of diseases | |
| Turan et al. | Evaluation of 99mTc-citrate, 67Gacitrate and 99mTc (V) dimercaptosuccinic acid for the scintigraphic visualization of acute appendicitis | |
| JPS63170400A (ja) | 放射性医薬品とその調製用高分子化合物 | |
| Rosenau | Dangers in the use of certain halogenated phthaleins as functional tests | |
| Järnerot et al. | Olsalazine does not increase the bile acid losses in subjects with a permanent ileostomy | |
| Balachandran et al. | Tissue Distribution of 14C-, 125I-, and 131I-Diphenylhydantoin in the Toadfish, Rat, and Human with Insulinomas | |
| Hurwitz et al. | Distribution of 67Ga Following Intravenous Administration: Effects of Disodium Edetate Therapy | |
| Shaeffer | Lack of enhanced lysis of fibrinogen-I131 by anticoagulants in tumor-bearing rats | |
| JPS60126231A (ja) | 放射性診断剤 |